WO2008111532A1 - インフルエンザワクチン含有凍結乾燥製剤、及びその製造方法 - Google Patents

インフルエンザワクチン含有凍結乾燥製剤、及びその製造方法 Download PDF

Info

Publication number
WO2008111532A1
WO2008111532A1 PCT/JP2008/054210 JP2008054210W WO2008111532A1 WO 2008111532 A1 WO2008111532 A1 WO 2008111532A1 JP 2008054210 W JP2008054210 W JP 2008054210W WO 2008111532 A1 WO2008111532 A1 WO 2008111532A1
Authority
WO
WIPO (PCT)
Prior art keywords
influenza vaccine
preparation
aqueous solution
lyophilized preparation
iii
Prior art date
Application number
PCT/JP2008/054210
Other languages
English (en)
French (fr)
Inventor
Chikamasa Yamashita
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08721627A priority Critical patent/EP2119451A4/en
Priority to UAA200910179A priority patent/UA97391C2/ru
Priority to US12/529,893 priority patent/US8216588B2/en
Priority to CA2680193A priority patent/CA2680193C/en
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Priority to JP2009504039A priority patent/JP5388842B2/ja
Priority to MX2009009635A priority patent/MX2009009635A/es
Priority to BRPI0808037-2A2A priority patent/BRPI0808037A2/pt
Priority to RU2009137380/15A priority patent/RU2484847C2/ru
Priority to NZ579395A priority patent/NZ579395A/en
Priority to CN2008800077114A priority patent/CN101631563B/zh
Priority to AU2008225501A priority patent/AU2008225501B2/en
Publication of WO2008111532A1 publication Critical patent/WO2008111532A1/ja
Priority to IL200588A priority patent/IL200588A0/en
Priority to ZA2009/05952A priority patent/ZA200905952B/en
Priority to HK10105830.1A priority patent/HK1139076A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16051Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

 本発明の目的は、インフルエンザワクチンの安定性が改善されている凍結乾燥製剤を提供することである。  以下の(A)~(C)の条件を充足する水溶液を凍結乾燥させることにより、インフルエンザワクチンの安定性が顕著に改善された凍結乾燥製剤を得る:(A)(i)インフルエンザワクチン、(ii)疎水性アミノ酸、及び(iii)アルギニン及びその酸付加塩を含む、(B)前記(iii)成分が、得られる凍結乾燥製剤の総量に対して20~85重量%となるように配合されている、及び(c)前記(iii)成分を構成するアルギニンとその酸付加塩の比率をコントロールすることによって、pH8~10に調整されている。
PCT/JP2008/054210 2007-03-09 2008-03-07 インフルエンザワクチン含有凍結乾燥製剤、及びその製造方法 WO2008111532A1 (ja)

Priority Applications (14)

Application Number Priority Date Filing Date Title
MX2009009635A MX2009009635A (es) 2007-03-09 2008-03-07 Preparacion liofilizada que comprende una vacuna para influenza y metodo para preparacion de la misma.
US12/529,893 US8216588B2 (en) 2007-03-09 2008-03-07 Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
CA2680193A CA2680193C (en) 2007-03-09 2008-03-07 Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
RU2009137380/15A RU2484847C2 (ru) 2007-03-09 2008-03-07 Лиофилизированный препарат, содержащий гриппозную вакцину, и способ его получения
JP2009504039A JP5388842B2 (ja) 2007-03-09 2008-03-07 インフルエンザワクチン含有凍結乾燥製剤、及びその製造方法
UAA200910179A UA97391C2 (ru) 2007-03-09 2008-03-07 Лиофилизированный препарат, содержащий гриппозную вакцину, и способ его получения
BRPI0808037-2A2A BRPI0808037A2 (pt) 2007-03-09 2008-03-07 Preparação liofilizada contendo vacina contra gripe e método para preparação da mesma.
EP08721627A EP2119451A4 (en) 2007-03-09 2008-03-07 LYOPHILIZED PREPARATION COMPRISING THE INFLUENZA VACCINE AND PREPARATION METHOD THEREOF
NZ579395A NZ579395A (en) 2007-03-09 2008-03-07 Influenza vaccine with improved presevation and stability properties comprising a hydrophobic amino acid, arginine and an acid addition salt
CN2008800077114A CN101631563B (zh) 2007-03-09 2008-03-07 含有流感疫苗的冻干制剂及其制备方法
AU2008225501A AU2008225501B2 (en) 2007-03-09 2008-03-07 Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
IL200588A IL200588A0 (en) 2007-03-09 2009-08-26 Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
ZA2009/05952A ZA200905952B (en) 2007-03-09 2009-08-27 Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
HK10105830.1A HK1139076A1 (en) 2007-03-09 2010-06-10 Lyophilized preparation comprising influenza vaccine, and method for preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007059724 2007-03-09
JP2007-059724 2007-03-09

Publications (1)

Publication Number Publication Date
WO2008111532A1 true WO2008111532A1 (ja) 2008-09-18

Family

ID=39759470

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/054210 WO2008111532A1 (ja) 2007-03-09 2008-03-07 インフルエンザワクチン含有凍結乾燥製剤、及びその製造方法

Country Status (20)

Country Link
US (1) US8216588B2 (ja)
EP (1) EP2119451A4 (ja)
JP (1) JP5388842B2 (ja)
KR (1) KR20090128463A (ja)
CN (1) CN101631563B (ja)
AR (1) AR065640A1 (ja)
AU (1) AU2008225501B2 (ja)
BR (1) BRPI0808037A2 (ja)
CA (1) CA2680193C (ja)
HK (1) HK1139076A1 (ja)
IL (1) IL200588A0 (ja)
MX (1) MX2009009635A (ja)
MY (1) MY149924A (ja)
NZ (1) NZ579395A (ja)
RU (1) RU2484847C2 (ja)
SG (1) SG179406A1 (ja)
TW (1) TWI428140B (ja)
UA (1) UA97391C2 (ja)
WO (1) WO2008111532A1 (ja)
ZA (1) ZA200905952B (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523243A (ja) * 2011-06-28 2014-09-11 ロイコケア・アクチェンゲゼルシャフト ウイルスまたは細菌の新規な安定化方法
WO2017090767A1 (ja) * 2015-11-27 2017-06-01 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
US10195242B2 (en) * 2013-01-25 2019-02-05 Wintermute Biomedical, Inc. Therapeutic compounds
JP2019163271A (ja) * 2013-09-03 2019-09-26 ジョージア テック リサーチ コーポレイション 熱安定性ワクチン製剤及びマイクロニードル
US11065220B2 (en) 2017-02-13 2021-07-20 Wintermute Biomedical, Inc. Anti-pathogenic therapeutic compositions
US11103475B2 (en) 2018-10-01 2021-08-31 Wintermute Biomedical, Inc. Therapeutic compositions of undecylenic acid and arginine

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
GB201314248D0 (en) * 2013-08-08 2013-09-25 Glaxosmithkline Biolog Sa Saccharide vaccine formulation
JP2016534070A (ja) * 2013-10-25 2016-11-04 ロイコケア・アクチェンゲゼルシャフト 安定化ワクチンの製造のための新規方法
WO2017090769A1 (ja) 2015-11-27 2017-06-01 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
WO2017090766A1 (ja) 2015-11-27 2017-06-01 日東電工株式会社 口腔内投与用ワクチン医薬組成物及び口腔内投与用ワクチン医薬組成物の製造方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58183628A (ja) * 1982-04-06 1983-10-26 アメリカン・サイアナミド・カンパニ− インフルエンザウイルスワクチンの安定化
JPH05320071A (ja) * 1992-05-22 1993-12-03 Biseibutsu Kagaku Kenkyusho:Kk 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ3型ウイルス感染症、牛rsウイルス感染症および牛アデノ7型ウイルス感染症5種混合生ワクチン
JPH0665096A (ja) * 1981-05-13 1994-03-08 Inst Pasteur 安定化されたワクチン及びその製造法
WO2001074397A1 (fr) * 2000-03-31 2001-10-11 Kirin Beer Kabushiki Kaisha Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree
WO2006041819A1 (en) * 2004-10-06 2006-04-20 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
JP2006519028A (ja) * 2003-02-25 2006-08-24 メッドイミューン バクシーンズ、インコーポレイティド インフルエンザワクチン組成物を生成する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07121871B2 (ja) * 1986-10-09 1995-12-25 国立予防衛生研究所長 インフルエンザワクチン凍結乾燥製剤
JPH05229960A (ja) * 1990-10-30 1993-09-07 Dai Ichi Seiyaku Co Ltd 新規インフルエンザワクチン
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
JP2004054555A (ja) * 2002-07-19 2004-02-19 Yokogawa Electric Corp 表示装置
RU2290205C1 (ru) * 2005-09-13 2006-12-27 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунологическим препаратам "МИКРОГЕН" Министерства здравоохранения Российской Федерации Способ получения живой вакцины для профилактики гриппа

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0665096A (ja) * 1981-05-13 1994-03-08 Inst Pasteur 安定化されたワクチン及びその製造法
JPS58183628A (ja) * 1982-04-06 1983-10-26 アメリカン・サイアナミド・カンパニ− インフルエンザウイルスワクチンの安定化
JPH05320071A (ja) * 1992-05-22 1993-12-03 Biseibutsu Kagaku Kenkyusho:Kk 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ3型ウイルス感染症、牛rsウイルス感染症および牛アデノ7型ウイルス感染症5種混合生ワクチン
WO2001074397A1 (fr) * 2000-03-31 2001-10-11 Kirin Beer Kabushiki Kaisha Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree
JP2006519028A (ja) * 2003-02-25 2006-08-24 メッドイミューン バクシーンズ、インコーポレイティド インフルエンザワクチン組成物を生成する方法
WO2006041819A1 (en) * 2004-10-06 2006-04-20 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEBORAH A. BUONAGURIO ET AL., VACCINE, vol. 24, 2006, pages 2151 - 2160
ROBERT J. GARMISE ET AL., AAPS PHARMSCITECH, vol. 7, no. 1, 2006, pages E1 - E7
See also references of EP2119451A4
STEPHEN E. ZWEIG, VACCINE, vol. 24, 2006, pages 5977 - 5985

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523243A (ja) * 2011-06-28 2014-09-11 ロイコケア・アクチェンゲゼルシャフト ウイルスまたは細菌の新規な安定化方法
JP2017123861A (ja) * 2011-06-28 2017-07-20 ロイコケア・アクチェンゲゼルシャフト ウイルスまたは細菌の新規な安定化方法
US10195242B2 (en) * 2013-01-25 2019-02-05 Wintermute Biomedical, Inc. Therapeutic compounds
JP2019163271A (ja) * 2013-09-03 2019-09-26 ジョージア テック リサーチ コーポレイション 熱安定性ワクチン製剤及びマイクロニードル
JP7358068B2 (ja) 2013-09-03 2023-10-10 ジョージア テック リサーチ コーポレイション 熱安定性ワクチン製剤及びマイクロニードル
WO2017090767A1 (ja) * 2015-11-27 2017-06-01 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
US11065220B2 (en) 2017-02-13 2021-07-20 Wintermute Biomedical, Inc. Anti-pathogenic therapeutic compositions
US11103475B2 (en) 2018-10-01 2021-08-31 Wintermute Biomedical, Inc. Therapeutic compositions of undecylenic acid and arginine
US11154524B2 (en) 2018-10-01 2021-10-26 Wintermute Biomedical, Inc. Therapeutic compositions of decanoic acid and arginine

Also Published As

Publication number Publication date
EP2119451A4 (en) 2012-05-16
JPWO2008111532A1 (ja) 2010-06-24
CA2680193A1 (en) 2008-09-18
AU2008225501B2 (en) 2013-08-29
HK1139076A1 (en) 2010-09-10
US8216588B2 (en) 2012-07-10
EP2119451A1 (en) 2009-11-18
UA97391C2 (ru) 2012-02-10
MX2009009635A (es) 2009-09-22
BRPI0808037A2 (pt) 2014-06-17
MY149924A (en) 2013-10-31
CA2680193C (en) 2015-05-05
KR20090128463A (ko) 2009-12-15
NZ579395A (en) 2012-05-25
IL200588A0 (en) 2010-05-17
RU2009137380A (ru) 2011-04-20
TW200848074A (en) 2008-12-16
AR065640A1 (es) 2009-06-17
AU2008225501A2 (en) 2009-09-24
RU2484847C2 (ru) 2013-06-20
CN101631563A (zh) 2010-01-20
US20100104595A1 (en) 2010-04-29
TWI428140B (zh) 2014-03-01
ZA200905952B (en) 2010-11-24
JP5388842B2 (ja) 2014-01-15
SG179406A1 (en) 2012-04-27
CN101631563B (zh) 2013-07-24
AU2008225501A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2008111532A1 (ja) インフルエンザワクチン含有凍結乾燥製剤、及びその製造方法
WO2008045563A3 (en) Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
WO2010149743A3 (en) Vaccine
WO2014066468A8 (en) Stable, low viscosity antibody formulation
WO2012015810A3 (en) Pharmaceutical compositions containing pemetrexed having extended storage stability
MY156305A (en) Pharmaceutical composition
BR112012004051A8 (pt) formulação de concentrado aquoso, uso da formulação de concentrado aquoso e metodo para controlar vegetação indesejada
WO2007014258A3 (en) Growth hormone secretagogues
WO2009041062A1 (ja) 血漿中動態が改善されたグリピカン3抗体
DE502006006185D1 (de) Verfahren zur herstellung einer wässrigen suspension und einer pulverförmigen zubereitung eines oder mehrerer carotinoide
NZ600891A (en) Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
WO2012140127A3 (en) Method for priming of t cells
WO2008133330A1 (ja) 4,5-エポキシモルヒナン誘導体を含有する安定な固形製剤
WO2010088565A8 (en) Nucleic acid delivery using modified chitosans
WO2009118754A3 (en) A process for preparing a stable lyophilized composition
WO2011016049A3 (en) A stable composition of ready-to-use gemcitabine injection
WO2006028649A3 (en) Compositions of water-insoluble active organic compounds
BR112012010149A2 (pt) composto de paclitaxel / esteroidal
EP2103610A4 (en) SALTS OF IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES, METHOD OF MANUFACTURE AND USE THEREOF
WO2009130181A3 (en) Dry transglutaminase composition
WO2011051916A3 (en) Stabilized protein formulations and use thereof
WO2008074488A3 (en) Construction and use of transfection enhancer elements
WO2007143143A3 (en) Composition for enhancing muscle recovery
WO2007104934A3 (en) Protein folding
WO2009113033A3 (en) Linear and cyclic guanidine derivatives, method of preparation and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880007711.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721627

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12009501584

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2008225501

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200588

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 5582/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 579395

Country of ref document: NZ

Ref document number: 2008721627

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12529893

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2680193

Country of ref document: CA

Ref document number: 2009504039

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009091330

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/009635

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008225501

Country of ref document: AU

Date of ref document: 20080307

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 09111146

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20097020993

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009137380

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0808037

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090828